Patents by Inventor Charles E. Weeks

Charles E. Weeks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of ?5-androstene-3?-ol-7,17-dione in the treatment of lupus erythematosus
    Patent number: 6924274
    Abstract: Lupus erythematosus can be treated by administering therapeutic amounts of ?5-androstene-3?-ol-7,17-dione and metabolizable precursors thereof, such as ?5-androstene-3b-acetoxy-7,17-dione, which are readily metabolized in vivo to ?5-androstene-3?-ol-7,17-dione but are not appreciably metabolizable in vivo to androgens, estrogens or dehydroepiandrosterone. Such treatment can be prophylactic, ameliorative or curative in nature.
    Type: Grant
    Filed: May 8, 2003
    Date of Patent: August 2, 2005
    Assignee: Humanetic Corp.
    Inventors: Henry A. Lardy, Charles E. Weeks
  • Use of &Dgr;5-androstene-3&bgr;-OL7,17-dione in the treatment of arthritis
    Patent number: 6794374
    Abstract: Arthritis can be treated by administering therapeutic amounts of &Dgr;5-androstene-3&bgr;-ol-7,17-dione and metabolizable precursors thereof, such a &Dgr;5-androstene-3&bgr;-acetoxy-7,17-dione, which are readily metabolized in vivo to &Dgr;5-androstene-3&bgr;-ol-7,17-dione but are not appreciably metabolizable in vivo to androgens, estrogens or dehydroepiandrosterone. Such treatment can be prophylactic, ameliorative or curative in nature.
    Type: Grant
    Filed: November 27, 2000
    Date of Patent: September 21, 2004
    Assignee: Humanetics Corporation
    Inventor: Charles E. Weeks
  • Use of delta5-androstene-3beta-ol-7,17-dione in the treatment of lupus erythematosus
    Publication number: 20040048839
    Abstract: Lupus erythematosus can be treated by administering therapeutic amounts of &Dgr;5-androstene-3&bgr;-ol-7,17-dione and metabolizable precursors thereof, such as &Dgr;5-androstene-3b-acetoxy-7,17-dione, which are readily metabolized in vivo to &Dgr;5-androstene-3&bgr;-ol-7,17-dione but are not appreciably metabolizable in vivo to androgens, estrogens or dehydroepiandrosterone. Such treatment can be prophylactic, ameliorative or curative in nature.
    Type: Application
    Filed: May 8, 2003
    Publication date: March 11, 2004
    Inventors: Henry A. Lardy, Charles E. Weeks
  • Use of &Dgr;5-androstene-3&bgr;ol-7,17-dione in the treatment of lupus erythematosus
    Patent number: 6593316
    Abstract: Lupus erythematosus can be treated by administering therapeutic amounts of &Dgr;5-androstene-3&bgr;-ol-7,17-dione and metabolizable precursors thereof, such as &Dgr;5-androstene-3&bgr;-acetoxy-7,17-dione, which are readily metabolized in vivo to &Dgr;5-androstene-3&bgr;-ol-7,17-dione but are not appreciably metabolizable in vivo to androgens, estrogens or dehydroepiandrosterone. Such treatment can be prophylactic, ameliorative or curative in nature.
    Type: Grant
    Filed: March 22, 2002
    Date of Patent: July 15, 2003
    Inventors: Henry A. Lardy, Charles E. Weeks
  • Stimulating transport of glucose into animal tissue by the administration of pinitol
    Patent number: 6518318
    Abstract: Enhanced muscle performance, including strength, recovery and endurance can be achieved by means of improved glucose transport and improved glycogen loading within animal muscle tissue through the administration of an effective amount of a pinitol compound. Pinitol alone, or in combination with a synergistic amount of insulin, is effective for controlling insulin-dependent diabetes.
    Type: Grant
    Filed: May 30, 2001
    Date of Patent: February 11, 2003
    Inventor: Charles E. Weeks
  • Use of delta5-androstene-3beta ol-7,17-dione in the treatment of lupus erythematosus
    Publication number: 20020160989
    Abstract: Lupus erythematosus can be treated by administering therapeutic amounts of &Dgr;5-androstene-3&bgr;-ol-7,17-dione and metabolizable precursors thereof, such as &Dgr;5-androstene-3&bgr;-acetoxy-7,17-dione, which are readily metabolized in vivo to &Dgr;5-androstene-3&bgr;-ol-7,17-dione but are not appreciably metabolizable in vivo to androgens, estrogens or dehydroepiandrosterone. Such treatment can be prophylactic, ameliorative or curative in nature.
    Type: Application
    Filed: March 22, 2002
    Publication date: October 31, 2002
    Inventors: Henry A. Lardy, Charles E. Weeks
  • Use of delta5-androstene-3beta-ol-7, 17-dione in the treatment of lupus erythematosus
    Patent number: 6372732
    Abstract: Lupus erythematosus can be treated by administering therapeutic amounts of delta-5-androstene-3-beta-ol-7,17-dione and its metabolizable precursors, which are not appreciably metabolized in vivo to androgens, estrogens or dehydroepiandrosterone. Such treatment can be prophylactic, ameliorative or curative in nature.
    Type: Grant
    Filed: December 4, 2000
    Date of Patent: April 16, 2002
    Assignee: Humanetics Corporation
    Inventors: Henry A. Lardy, Charles E. Weeks
  • 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
    Patent number: 5266575
    Abstract: 2-Ethyl 1H-imidazo[4,5-c]quinolin-4-amines, which are active as immunomodulators and antiviral agents, and intermediates in the preparation of such compounds, pharmaceutical compositions and pharmacological methods of use.
    Type: Grant
    Filed: November 6, 1991
    Date of Patent: November 30, 1993
    Assignee: Minnesota Mining and Manufacturing Company
    Inventors: John F. Gerster, Charles E. Weeks